Crescent Biopharma, Inc. (CBIO) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.94
↓-100% vs avg
5yr avg: 212.83
30Y Low0.6·High189.2
ROE
↓
-164.2%
-1% vs avg
5yr avg: -162.7%
30Y Low-423%·High35%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CBIO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Crescent Biopharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $506M | $124M | $486M | $14.9B | $15.9B | $7.4B | $17.2B | $22.9B | $38.9B | $49.4B | $13.0B |
| Enterprise Value | $294M | $-88042123 | $488M | $14.9B | $15.9B | $7.3B | $17.1B | $22.7B | $38.7B | $49.2B | $12.9B |
| P/E Ratio → | -1.43 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 46.63 | 11.39 | — | 1494882.17 | 212225.94 | 6388.59 | 1691.55 | — | — | — | 700883.80 |
| P/B Ratio | 0.94 | 0.61 | — | 389.15 | 370.77 | 90.80 | 134.08 | 148.39 | 189.18 | 412.32 | 367.31 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
CBIO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -8.12 | — | 1490783.73 | 211599.91 | 6312.42 | 1678.35 | — | — | — | 698719.37 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
CBIO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Crescent Biopharma, Inc. earns an operating margin of -1407.5%. Operating margins have expanded from -392752.9% to -1407.5% over the past 3 years, signaling improving operational efficiency. A negative ROE of -164.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | — | — | — | — | — |
| Operating Margin | -1407.5% | -1407.5% | — | -392752.9% | -63204.4% | -5470.7% | -506.8% | — | — | — | -172505.3% |
| Net Profit Margin | -1419.6% | -1419.6% | — | -368994.2% | -62251.7% | -5469.0% | -502.1% | — | — | — | -171945.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -164.2% | -164.2% | -423.1% | -90.7% | -75.0% | -60.5% | -36.1% | -30.1% | -29.7% | -42.9% | -84.0% |
| ROA | -111.6% | -111.6% | -119.9% | -76.0% | -63.9% | -53.5% | -32.8% | -28.3% | -28.1% | -38.9% | -70.0% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
| ROCE | -132.6% | -132.6% | -154.8% | -96.5% | -75.6% | -59.6% | -35.8% | -33.8% | -31.6% | -43.4% | -83.1% |
CBIO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $213M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | — | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.04 | — | -1.07 | -1.09 | -1.08 | -1.05 | -1.00 | -1.02 | -1.04 | -1.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -68.54 | -68.54 | -51.89 | — | — | — | — | — | — | — | — |
Net cash position: cash ($213M) exceeds total debt ($2M)
CBIO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Crescent Biopharma, Inc.'s current ratio of 6.56x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 6.41x to 6.56x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.56 | 6.56 | 3.62 | 6.41 | 5.71 | 7.68 | 11.13 | 14.84 | 24.22 | 15.56 | 6.40 |
| Quick Ratio | 6.56 | 6.56 | 3.62 | 6.41 | 5.71 | 7.68 | 11.13 | 14.84 | 24.22 | 15.56 | 6.37 |
| Cash Ratio | 5.91 | 5.91 | 3.62 | 6.11 | 5.39 | 7.63 | 11.03 | 14.45 | 23.95 | 15.16 | 6.32 |
| Asset Turnover | — | 0.05 | — | 0.00 | 0.00 | 0.01 | 0.07 | — | — | — | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 605.87 | — | 6417.43 | 700.88 | 0.42 | 0.08 | — | — | — | 5300.57 |
CBIO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Crescent Biopharma, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $10M | $20M | $63M | $53M | $51M | $46M | $43M | $41M | $29M | $21M |
Peer Comparison
Compare CBIO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CBIOYou | $506M | -1.4 | — | — | 100.0% | -1407.5% | -164.2% | — | — |
 RCUS | $2B | -7.1 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 KYMR | $7B | -22.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 TPST | $6M | -0.2 | — | — | — | — | -203.6% | -352.0% | — |
 AGEN | $141M | -997.1 | — | — | 29.6% | -18.0% | — | — | — |
 NKTR | $1B | -6.1 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 CRVS | $975M | -21.9 | — | — | — | — | -32.6% | -78.1% | — |
 EXEL | $14B | 19.2 | 14.7 | 16.1 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
 MGNX | $255M | -3.4 | — | — | 71.1% | -48.7% | -86.9% | -144.1% | — |
 FATE | $230M | -1.7 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
What if you invested $1,000 in CBIO 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in CBIO be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs CBIO Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCBIO vs RCUS — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Arcus Biosciences, Inc..
Compare NowCBIO — Frequently Asked Questions
Quick answers to the most common questions about buying CBIO stock.
What is Crescent Biopharma, Inc.'s P/E ratio?
Crescent Biopharma, Inc.'s current P/E ratio is -1.4x. This places it at the 50th percentile of its historical range.
What is Crescent Biopharma, Inc.'s ROE?
Crescent Biopharma, Inc.'s return on equity (ROE) is -164.2%. The historical average is -85.4%.
Is CBIO stock overvalued?
Based on historical data, Crescent Biopharma, Inc. is trading at a P/E of -1.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Crescent Biopharma, Inc.'s profit margins?
Crescent Biopharma, Inc. has 100.0% gross margin and -1407.5% operating margin.